AACR Special Conference - Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic
January 25, 2016
Patient-derived cancer models have become a very popular approach for preclinical drug development and biomarker discovery. This AACR Special Meeting will be the first to be entirely focused solely on patient-derived cancer models and their applications in basic, translational, and clinical research.
With the world’s largest collection of over 2,000 well-characterized patient-derived xenograft (PDX) models (HuPrime®) – large enough to be truly reflective of the patient population – Crown Bioscience enables drug discovery organizations to perform human surrogate Phase II-like mouse clinical trials, also known as HuTrials™, to identify suitable disease indications and discover and validate predictive biomarkers for their therapies. Crown’s capacity to perform large-scale studies, screening dozens of models in one single study, means that we can perform your HuTrial™ in months rather than years.
Dr. Henry Li VP of Translational Oncoloy at Crown will attend this meeting and will present data on our immuno-oncology translational research on Friday, February 12, 12:30 p.m.–3:30 p.m.
To receive a copy of Dr Li’s poster entitled “Modeling NK-mediated Immunotherapy on a NSCLC Patient-derived Xenograft”, come visit us in New Orleans or send us an email at email@example.com